Company / Shareholders' Equity
Travere Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$114.8M
FY2025
5-year range
$42.9M / $221.2M
FY2021-FY2025
Trend
+94.4%
vs FY2024
Sector context
#167 of 213
Health Care
What the data says
Travere Therapeutics, Inc.'s shareholders' equity of $115M is lower than 78% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from -$37M in FY2016 to $318M in FY2020.
Based on SEC 10-K filings.
$115M in FY2025 with a 5-year CAGR of -18.4%.
Declined from $201M to $115M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +38.9%
- 5-Year CAGR
- -18.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 213This company $114.8M Sector average $2.5B
▼
-95.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -18.4%, indicating a declining trend.
- In FY2025, shareholders' equity increased 94.4% year-over-year.
- Ranks #167 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.8M | +94.4% |
| FY2024 | $59.1M | -70.6% |
| FY2023 | $200.8M | +368.6% |
| FY2022 | $42.9M | -80.6% |
| FY2021 | $221.2M | -30.5% |
| FY2020 | $318.3M | +8.6% |
| FY2019 | $293.1M | -4.8% |
| FY2018 | $307.8M | +2.6% |
| FY2017 | $300.0M | +905.3% |
| FY2016 | -$37.3M | -112.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026